Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3568949 | 1.00 | — | — | |
| SCHEMBL105170 | 0.97 | — | — | |
| Bromide SCHEMBL2295025 | 0.95 | — | — | |
| SCHEMBL3538758 | 0.90 | — | — | |
| Iodide SCHEMBL10973537 | 0.87 | — | — | |
| SCHEMBL5563394 | 0.87 | NOS3 (0.81) | — | |
| SCHEMBL5563387 | 0.87 | NOS3 (0.81) | — | |
| SCHEMBL5563390 | 0.87 | NOS3 (0.81) | — | |
| Hydrochloric Acid SCHEMBL4827026 | 0.83 | — | — | |
| SCHEMBL127079 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247018-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-112638876-B | phenyl/pyridinyl-N-phenyl/pyridinyl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3820849-B1 | PHENYL/PYRIDYL-NH-PHENYL/PYRIDYL DERIVATIVES FOR TREATING RNA VIRUS INFECTION | ABIVAX (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-20220356175-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2022-11-10 | — | — | US | disclosed |
| CN-112638876-A | phenyl/pyridyl-N-phenyl/pyridyl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-1252162-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1326847-B1 | (2S)-2-(ADAMANTAN-1-YLMETHOXYCARBONYLAMINO)-3-(4-(2-(1,4,5,6-TETRAHYDROPYRIMIDIN-2-YLCARBAMOYL)ETHYL)BENZOYLAMINO)PROPIONIC ACID ISOPROPYL ESTER, ITS PREPARATION AND ITS USE | AVENTIS PHARMA GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-7462621-B2 | Use of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| CN-1179418-A | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-04-22 | — | — | CN | disclosed |
| EP-0820991-A2 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0796855-A1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
| EP-0158020-B1 | PROCESS FOR PREPARING 2-HYDRAZINO-1,3-DIAZACYCOALK-2-ENE HYDROHALIDES | AMERICAN CYANAMID COMPANY (US) | 1988-05-25 | — | — | EP | disclosed |
| US-4574155-A | Process for preparing 2-hydrazino-1,3-diazacycloalk-2-ene hydrohalides | AMERICAN CYANAMID COMPANY (US) | 1986-03-04 | — | — | US | disclosed |
| EP-0042279-B1 | N-ARYL-N'((1,4,5,6-TETRAHYDROPYRIMIDIN-2-YL) OR (4,5,6,7-TETRAHYDRO-1-H-1, 3-DIAZEPIN-2-YL)UREAS FOR INTESTINAL DISORDERS AND AS ANTIHYPERTENSIVES | McNeilab, Inc. (US) | 1985-11-13 | — | — | EP | disclosed |
| EP-0158020-A1 | Process for preparing 2-hydrazino-1,3-diazacycoalk-2-ene hydrohalides | AMERICAN CYANAMID COMPANY (US) | 1985-10-16 | — | — | EP | disclosed |
| US-4466966-A | N-aryl-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)ureas for intestinal disorders | MCNEILAB, INC. (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0042279-A2 | N-aryl-N'((1,4,5,6-tetrahydropyrimidin-2-yl) or (4,5,6,7-tetrahydro-1-H-1, 3-diazepin-2-yl)ureas for intestinal disorders and as antihypertensives | McNeilab, Inc. (US) | 1981-12-23 | — | — | EP | disclosed |
| US-4285948-A | ADMINISTERING CARDIOTONIC AGENTS | MCNEILAB, INC. (US) | 1981-08-25 | — | — | US | disclosed |